Vanda Pharmaceuticals Surges 45% Following FDA Approval of BYSANTI

Shares of Vanda Pharmaceuticals (VNDA) experienced a massive rally of approximately 45% following a major regulatory breakthrough. The U.S. Food and Drug Administration (FDA) granted approval for the company's new drug, BYSANTI, for the treatment of schizophrenia and bipolar I disorder. This approval serves as a significant fundamental catalyst for the biotech firm, which had previously been struggling with disappointing earnings reports. Notably, the drug has been granted "New Chemical Entity" (NCE) status, ensuring robust patent protection until 2044. Market observers suggest the sharp price increase may have been amplified by a potential short squeeze triggered by the positive news. While the long-term sustainability of the jump remains to be seen, the approval significantly strengthens Vanda's competitive position in the pharmaceutical market.